ZOLL Goes Red: Tackling the Gender Gap in Women's Heart Health

CHELMSFORD, Mass. – February 02, 2026 – As Heart Month begins, a new initiative is casting a bright red spotlight on a persistent and often deadly disparity in healthcare: the gender gap in cardiovascular disease. Medical device manufacturer ZOLL announced its “ZOLL LifeVest Goes Red” campaign, a comprehensive partnership with the American Heart Association's renowned Go Red for Women® initiative aimed at raising awareness, funds, and advocating for better cardiac outcomes for women.

The campaign comes at a critical time. While heart disease is the leading cause of death for both men and women, its impact on women is frequently misunderstood and undertreated. ZOLL, an Asahi Kasei company, is leveraging its position as a leader in cardiac management solutions to address this gap, combining corporate advocacy with the proven technology of its LifeVest® wearable cardioverter defibrillator (WCD).

“During Heart Month, we reaffirm our commitment to supporting women at risk of sudden cardiac death and to working alongside healthcare providers to improve outcomes for patients when they are most vulnerable,” said Mike Blastick, President of ZOLL Cardiac Management Solutions, in a statement. The company's employees will be participating in fundraising events throughout February, with ZOLL matching all donations to benefit the American Heart Association.

The Alarming Gender Gap in Cardiac Care

For decades, the image of a heart attack victim has been predominantly male. This misconception has had dire consequences, as cardiovascular disease kills more women in the United States than all forms of cancer combined, accounting for one in every five female deaths. According to the American Heart Association, over 62 million women in the U.S. are living with some form of heart disease, yet studies show only about half of them recognize it as their primary health threat.

The disparities go far beyond awareness. Women are more likely than men to die within a year of their first heart attack, and they face a 20% higher risk of developing heart failure or dying within five years compared to their male counterparts. A significant part of the problem lies in diagnosis. Women often experience atypical heart attack symptoms—such as nausea, extreme fatigue, and jaw or back pain—rather than the classic crushing chest pain. This can lead to delayed treatment or misdiagnosis, with devastating results.

Furthermore, certain risk factors impact women more severely. Diabetes and high blood pressure, for instance, increase cardiovascular risk more significantly in women. Unique life stages also play a critical role. Conditions like peripartum cardiomyopathy (PPCM), a rare form of heart failure that occurs during or after pregnancy, present exclusive challenges that require specialized attention and care. This silent epidemic underscores a pressing need for tailored interventions and technologies designed with women's unique physiology and health journey in mind.

A Technological Lifeline for Women at Risk

At the forefront of ZOLL's campaign is the LifeVest, a wearable cardioverter defibrillator prescribed to patients at risk of sudden cardiac death (SCD). Worn discreetly under clothing, the device continuously monitors a patient's heart rhythm. If it detects a life-threatening arrhythmia, it can automatically deliver a treatment shock to restore a normal rhythm, providing a crucial bridge to recovery or long-term treatment.

For women, the device has proven to be particularly vital. LifeVest is the most prescribed WCD for women, having already protected nearly 400,000 female patients. Clinical data suggests that women exhibit higher compliance rates with the device than men, wearing it for a median of over 23 hours a day. This high level of adherence is critical for ensuring protection during a vulnerable period, such as after a heart attack or while managing heart failure.

Significantly, ZOLL's commitment to women's health is reflected in its research. LifeVest is the only WCD that has been specifically studied in patients with peripartum cardiomyopathy, the pregnancy-related heart condition. This research provides invaluable data for a patient group that has historically been underrepresented in clinical trials. Studies have also shown that arrhythmias are detected more frequently in female LifeVest patients, highlighting the device's role in identifying and treating potentially fatal events that might otherwise go unnoticed. With a newly designed garment praised by patients for its enhanced comfort, the technology is becoming an even more integrated and less intrusive part of daily life for those who depend on it.

Beyond a Campaign: A Strategic Corporate Commitment

The "Goes Red" initiative is not a fleeting act of corporate philanthropy but the latest chapter in a long-standing strategic partnership between ZOLL and the American Heart Association. The Pittsburgh-based Cardiac Management Solutions division has been a consistent supporter of its local AHA chapter, embedding its mission of saving lives deep within the community.

This commitment extends to tangible public health infrastructure. ZOLL has sponsored one of the country's most utilized hands-only CPR training kiosks at the Kamin Science Center in Pittsburgh, empowering thousands of citizens with life-saving skills. The company has also funded Project Lifesaver, a program that provides bystander CPR training in under-resourced neighborhoods with disproportionately high rates of sudden cardiac death.

By annually sponsoring key AHA events like the Heart Walk, the Heart Ball, and Go Red for Women, ZOLL demonstrates a sustained investment in the cardiovascular health ecosystem. This approach creates a powerful synergy: the AHA's advocacy and public education efforts raise awareness of the risks women face, while ZOLL provides a clinically proven technological solution to mitigate one of the most severe of those risks—sudden cardiac death. This alignment reinforces the company's market position while contributing meaningfully to a pressing public health cause.

Amplifying a National Movement

ZOLL's campaign lends powerful corporate support to the American Heart Association's Go Red for Women movement, an initiative that has fundamentally changed the conversation around women's heart health since its launch in 2004. Before the campaign, a mere 30% of women recognized heart disease as their number one killer. Today, that figure has risen to 56%.

The impact is measured in lives. The AHA credits the movement with helping save over 3 million women's lives over the past two decades, with nearly 300 fewer women dying from heart disease and stroke each day. The campaign's iconic red dress symbol has become a national emblem of awareness and empowerment, encouraging women to take charge of their health through education, lifestyle changes, and advocacy.

By "going red," ZOLL is not just raising funds; it is amplifying this life-saving message across its corporate and customer networks. Through Go Red-themed social media campaigns and employee engagement, the company is helping to disseminate critical information about cardiac risk factors and treatment options for women. This collaborative effort between a leading medical technology firm and a premier public health organization illustrates a modern, effective model for tackling complex health challenges, combining the reach of advocacy with the precision of advanced medical care.